Author: NewsCancer

Teylu, a not-for-profit community group, has been given free rehearsal space at a company called Boost in Liskeard, Cornwall, which makes breast forms for people who have undergone surgery. Bernice Strickland has had a mammoplasty – a breast reduction to remove the cancer – and she wears one of the Boost breast forms. “It has been a very powerful experience. I was diagnosed with breast cancer last year and after surgery I was supported by lots of people within our theatre company and that support means absolutely everything.”So many people who have a cancer journey have to have radiotherapy and…

Study design and patient inclusionThis study was conducted at University Hospital Augsburg over a two-year period from December 2018 to November 2020. 40 Patients were enrolled as part of a prospective colorectal cancer (CRC) cohort, for which previous investigations have also been published4,15,21. The present evaluation represents a post hoc analysis of this cohort. All included patients underwent surgical treatment without receiving neoadjuvant therapy. Surgery was performed according to established guidelines for UICC tumor stages I–III22.To minimize confounding factors influencing immune function, patients with acute or chronic infections, inherited or acquired immunodeficiencies, autoimmune disorders, or concomitant malignancies were excluded from…

Wanting to share her knowledge, Lynette spoke to other women, joined patient forums, attended BRCA research meetings, met scientists, and began raising money for research.She has also published her story – described as “remarkable” by oncologists and other cancer survivors – in a book.As Lynette describes in her book, Unbroken, knowledge is power and talking to other patients encouraged her to have tailored platinum chemotherapy and to come off the drug tamoxifen – which was not suitable for her. Her personalised treatment plan included PARP inhibitors.Her story doesn’t finish after breast cancer. Six months after finishing that treatment the cancer…

Colorectal cancer (CRC) progression and therapeutic resistance are strongly associated with the ability of tumor cells to evade apoptosis through the dysregulation of key anti-apoptotic pathways. Among the molecular mechanisms involved in CRC progression, microRNAs (miRNAs) have emerged as key post-transcriptional regulators of pathways controlling tumor growth, invasion, therapeutic response, and cell survival. We previously demonstrated that miR-195-5p acts as a tumor suppressor in CRC by impairing proliferation, migration, invasion, and cell-cycle progression. However, its contribution to the regulation of apoptotic signaling remains incompletely understood. In this study, we aimed to investigate the role of miR-195-5p as a regulator of…

While his illness is terminal, Josh said keeping his sense of humour and making memories remained his top priorities, as well as raising awareness to boost brain tumour research funding.In January, Josh started having “these weird feelings” but “thought nothing of it”. “I just thought I was tired,” he recalled.”February is when it started properly. I had a 10-day headache. I would be walking my dog with my wife or talking to my mum and dad, and I’d feel zoned out. I found out later it was mini seizures and I didn’t realise. It’s really scary to look back on.”On…

Adult B-ALL exhibits significant heterogeneity and poor prognosis compared with the pediatric population. While the complete remission (CR) rate of traditional induction chemotherapy is 70%–90% for newly diagnosed patients [1], only 30–50% of patients attain long-term disease-free survival (DFS) exceeding 5-years [2]. For the Philadelphia chromosome-positive (ph+) patients, the addition of tyrosine kinase inhibitors (TKIs) significantly improved the CR rates [3]. In addition, achieving measurable residual disease (MRD) negativity (<10−4 leukemic blasts), particularly early MRD negativity, is a critical determinant for long-term survival and reduces relapse [4]. Despite improvements in CR rates with traditional therapy, approximately half of them are…

Developers at Sunny Pharmtech have issued a voluntary nationwide recall of 3 lots of cyclophosphamide for injection, USP, to the user level because of the presence of particulate matter identified as steel, according to a company announcement posted by the FDA.¹The recall affects 1-g and 2-g single-dose vials distributed to wholesalers, distributors, hospitals, and pharmacies from May 2024 to October 2024. As of the announcement, no adverse events (AEs) or injuries associated with the particulate matter issue had been reported.Why was cyclophosphamide for injection recalled?The recall was initiated because of particulate matter identified as steel found in the affected product.…

The Celebrity Hunted series is in aid of Stand Up To Cancer and Dowden was determined to show the reality of life after diagnosis.She had to balance life on the run with her regular treatment, allowing the cameras to follow her as she received chemotherapy injections.”It was important to show the reality of cancer,” she said.”Unfortunately, a cancer diagnosis is like a life sentence.”Dowden said she hoped to start conversations in people’s homes about the realities of facing up to cancer.It also had an impact on her partner with Gu saying that it was “hard” to see Dowden have her…

While the all-oral regimen of decitabine/cedazuridine (DEC-C; Inqovi) plus venetoclax (Venclexta) for patients with acute myeloid leukemia (AML) maximizes patient convenience, clinicians who use oral specialty oncology medications can face distinct insurance hurdles compared with medical-benefit intravenous therapies. CancerNetwork® spoke with Michael R. Savona, MD, professor of internal medicine and cancer biology and director of the Hematologic Malignancies Research and Early Therapy Program at Vanderbilt University Medical Center; and Courtney D. DiNardo, MD, MSCE, professor in the Department of Leukemia and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, about how they and their teams…

Risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), met its primary end point of progression-free survival (PFS) in the phase 3 ARTEMIS-011 trial (NCT06935409) for patients with relapsed osteosarcoma, according to a news release from GSK.1The ARTEMIS-011 trial enrolled patients with osteosarcoma who had progressed or relapsed after at least 2 prior lines of systemic therapy. Ris-Rez demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy, and a consistent benefit was also observed across secondary end points, including overall survival (OS). The safety profile in ARTEMIS-011 was consistent with prior findings in this tumor type, and…